What one share of Aquestive Therapeutics holds
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies.
Aquestive Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.45 |
|---|---|
| Profit | −$0.65 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.38 |
| Cash and investments | $0.78 |
| Debt | $0.44 |
| Book value | −$0.45 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $3.25 | −$2.96 | $0.09 | −$0.71 | — | $0.40 |
| 2019 | $2.07 | −$2.61 | $0.03 | −$2.40 | — | −$0.18 |
| 2020 | $1.36 | −$1.66 | $0.02 | −$1.37 | — | −$1.40 |
| 2021 | $1.33 | −$1.85 | $0.02 | −$0.89 | — | −$1.99 |
| 2022 | $0.98 | −$1.12 | $0.02 | −$0.22 | — | −$2.16 |
| 2023 | $0.83 | −$0.13 | $0.02 | −$0.12 | — | −$1.55 |
| 2024 | $0.66 | −$0.51 | $0.00 | −$0.41 | — | −$0.66 |
| 2025 | $0.42 | −$0.78 | $0.01 | −$0.50 | — | −$0.28 |
Common questions about Aquestive Therapeutics
How much does one share of Aquestive Therapeutics earn?
Over the last 12 months, Aquestive Therapeutics lost $0.65 for each share on $0.45 of sales.
Does Aquestive Therapeutics pay a dividend?
Aquestive Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Aquestive Therapeutics’s book value per share?
Aquestive Therapeutics’s book value is negative (−$0.45 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Aquestive Therapeutics have?
Each share of Aquestive Therapeutics has $0.78 of cash and investments and $0.44 of debt, as of June 30, 2026.
What is Aquestive Therapeutics’s free cash flow per share?
−$0.38 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Aquestive Therapeutics bought back shares?
Aquestive Therapeutics’s share count rose about 416% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.